Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDSX Biodesix	$0.45 +6.8%	$0.31	$0.17 ▼ $2.04	$61.22M	0.97	1.06 million shs	1.53 million shs
ELV Elevance Health	$289.11 +3.1%	$360.79	$274.40 ▼ $567.26	$63.15B	0.6	2.86 million shs	4.81 million shs
HOLX Hologic	$66.50 +0.6%	$63.33	$51.90 ▼ $84.67	$14.73B	0.55	1.80 million shs	1.12 million shs
ITGR Integer	$108.17 +1.0%	$118.78	$104.93 ▼ $146.36	$3.74B	0.98	474,587 shs	614,623 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDSX Biodesix	+6.80%	+39.71%	+65.28%	-17.24%	-72.63%
ELV Elevance Health	+3.15%	+4.42%	-22.75%	-31.42%	-43.55%
HOLX Hologic	+0.61%	+3.92%	+3.47%	+14.62%	-15.11%
ITGR Integer	+0.67%	-3.86%	-10.38%	-12.34%	-13.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDSX Biodesix	4.2321 of 5 stars	4.4	5.0	0.0	0.0	3.5	2.5	0.6
ELV Elevance Health	4.9526 of 5 stars	4.3	3.0	4.2	0.0	3.1	3.3	3.1
HOLX Hologic	4.7289 of 5 stars	3.2	3.0	0.0	4.3	2.9	3.3	1.9
ITGR Integer	3.3848 of 5 stars	3.5	1.0	0.0	0.0	2.4	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDSX Biodesix	2.80	Moderate Buy	$1.75	292.29% Upside
ELV Elevance Health	2.67	Moderate Buy	$418.19	44.65% Upside
HOLX Hologic	2.47	Hold	$77.33	16.29% Upside
ITGR Integer	3.00	Buy	$140.25	29.66% Upside

Current Analyst Ratings Breakdown

Latest ITGR, BDSX, ELV, and HOLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/25/2025	ELV Elevance Health	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$492.00 ➝ $297.00
7/25/2025	ITGR Integer	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$150.00 ➝ $143.00
7/25/2025	ITGR Integer	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $137.00
7/25/2025	ITGR Integer	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$152.00 ➝ $132.00
7/22/2025	ELV Elevance Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$472.00 ➝ $384.00
7/21/2025	ELV Elevance Health	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
7/18/2025	ELV Elevance Health	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$434.00 ➝ $358.00
7/18/2025	ELV Elevance Health	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$447.00 ➝ $360.00
7/18/2025	ELV Elevance Health	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$510.00 ➝ $310.00
7/18/2025	ELV Elevance Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$428.00 ➝ $316.00
7/17/2025	ELV Elevance Health	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDSX Biodesix	$74.46M	0.88	N/A	N/A	$0.14 per share	3.19
ELV Elevance Health	$177.01B	0.37	$40.38 per share	7.16	$194.74 per share	1.48
HOLX Hologic	$4.03B	3.68	$5.53 per share	12.02	$22.09 per share	3.01
ITGR Integer	$1.72B	2.20	$9.00 per share	12.02	$48.82 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDSX Biodesix	-$42.93M	-$0.29	N/A	N/A	N/A	-54.28%	-167.28%	-39.96%	8/7/2025 (Estimated)
ELV Elevance Health	$5.98B	$23.50	12.30	7.40	1.03	2.83%	17.59%	6.36%	N/A
HOLX Hologic	$789.50M	$2.37	28.06	14.39	2.42	13.83%	19.71%	10.87%	7/30/2025 (Estimated)
ITGR Integer	$119.90M	$2.11	47.65	16.27	0.92	4.61%	12.27%	6.23%	N/A

Latest ITGR, BDSX, ELV, and HOLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BDSX Biodesix	-$0.07	N/A	N/A	N/A	$18.47 million	N/A
7/30/2025	Q3 2025	HOLX Hologic	$1.05	N/A	N/A	N/A	$1.01 billion	N/A
7/24/2025	Q2 2025	ITGR Integer	$1.57	$1.55	-$0.02	$1.04	$464.37 million	$476.00 million
7/17/2025	Q2 2025	ELV Elevance Health	$9.30	$8.84	-$0.46	$7.72	$48.26 billion	$49.42 billion
5/13/2025	Q1 2025	BDSX Biodesix	-$0.08	-$0.08	N/A	-$0.08	$19.50 million	$17.96 million
5/1/2025	Q2 2025	HOLX Hologic	$1.02	$1.03	+$0.01	-$0.08	$1.00 billion	$1.01 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDSX Biodesix	N/A	N/A	N/A	N/A	N/A
ELV Elevance Health	$6.84	2.37%	N/A	29.11%	14 Years
HOLX Hologic	N/A	N/A	N/A	N/A	N/A
ITGR Integer	N/A	N/A	N/A	N/A	N/A

Latest ITGR, BDSX, ELV, and HOLX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/18/2025	ELV Elevance Health	quarterly	$1.71	2.5%	9/10/2025	9/10/2025	9/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDSX Biodesix	3.32	2.22	2.22
ELV Elevance Health	0.64	1.44	1.44
HOLX Hologic	0.54	3.24	2.52
ITGR Integer	0.72	3.41	2.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDSX Biodesix	20.96%
ELV Elevance Health	89.24%
HOLX Hologic	94.73%
ITGR Integer	99.29%

Insider Ownership

Company	Insider Ownership
BDSX Biodesix	30.10%
ELV Elevance Health	0.29%
HOLX Hologic	1.88%
ITGR Integer	2.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDSX Biodesix	220	146.56 million	102.45 million	Optionable
ELV Elevance Health	104,200	225.18 million	224.53 million	Optionable
HOLX Hologic	7,063	222.85 million	218.66 million	Optionable
ITGR Integer	11,000	34.89 million	34.14 million	Optionable

ITGR, BDSX, ELV, and HOLX Headlines

Recent News About These Companies

Raymond James Financial Has Lowered Expectations for Integer (NYSE:ITGR) Stock Price

July 26 at 12:00 PM | marketbeat.com

Truist Financial Cuts Integer (NYSE:ITGR) Price Target to $137.00

July 26 at 11:40 AM | marketbeat.com

Integer (NYSE:ITGR) Given New $132.00 Price Target at Wells Fargo & Company

July 26 at 10:28 AM | marketbeat.com

Neo Ivy Capital Management Invests $1.53 Million in Integer Holdings Corporation (NYSE:ITGR)

July 26 at 6:59 AM | marketbeat.com

Integer Posts 19 Percent EPS Gain in Q2

July 26 at 4:31 AM | theglobeandmail.com

Citi Remains a Buy on Integer Holdings (ITGR)

July 26 at 4:31 AM | theglobeandmail.com

3ITGR : 5 Analysts Have This To Say About Integer Holdings

July 26 at 4:31 AM | benzinga.com

Integer Holdings Corporation (ITGR) Q2 2025 Earnings Call Transcript

July 25 at 8:03 PM | seekingalpha.com

Integer Holdings Corporation 2025 Q2 - Results - Earnings Call Presentation

July 25 at 7:44 PM | seekingalpha.com

Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y

July 25 at 1:26 PM | zacks.com

Integer (NYSE:ITGR) Shares Down 7.2% After Earnings Miss

July 25 at 11:53 AM | marketbeat.com

Integer (NYSE:ITGR) Releases FY 2025 Earnings Guidance

July 25 at 9:26 AM | marketbeat.com

Readystate Asset Management LP Has $325,000 Holdings in Integer Holdings Corporation (NYSE:ITGR)

July 25 at 4:45 AM | marketbeat.com

Integer Holdings shares drop 5% despite revenue surpassing estimates

July 24 at 3:59 PM | msn.com

Integer posts Q2 sales beat but stock dips on EPS miss

July 24 at 3:59 PM | massdevice.com

Integer Holdings’s (NYSE:ITGR) Q2: Beats On Revenue But Stock Drops

July 24 at 3:59 PM | finance.yahoo.com

Why Integer Holdings (ITGR) Stock Is Down Today

July 24 at 3:59 PM | msn.com

Integer (ITGR) Q2 Earnings Lag Estimates

July 24 at 10:17 AM | zacks.com

Integer Holdings Corporation Reports Second Quarter 2025 Results

July 24 at 8:00 AM | globenewswire.com

Integer Holdings Corporation (NYSE:ITGR) Shares Sold by Victory Capital Management Inc.

July 23 at 4:12 AM | marketbeat.com

What To Expect From Integer Holdings’s (ITGR) Q2 Earnings

July 22, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
These 3 Undervalued Stocks Could Surge as Value Rotation Nears
By Gabriel Osorio-Mazilli | July 14, 2025
View These 3 Undervalued Stocks Could Surge as Value Rotation Nears

ITGR, BDSX, ELV, and HOLX Company Descriptions

Biodesix NASDAQ:BDSX

$0.45 +0.03 (+6.80%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$0.45 +0.00 (+0.87%)

As of 07/25/2025 07:58 PM Eastern

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Elevance Health NYSE:ELV

$289.11 +8.68 (+3.10%)

Closing price 07/25/2025 03:59 PM Eastern

Extended Trading

$289.87 +0.76 (+0.26%)

As of 07/25/2025 07:59 PM Eastern

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Hologic NASDAQ:HOLX

$66.50 +0.40 (+0.61%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$66.49 -0.01 (-0.02%)

As of 07/25/2025 04:29 PM Eastern

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Integer NYSE:ITGR

$108.17 +1.07 (+1.00%)

Closing price 07/25/2025 03:59 PM Eastern

Extended Trading

$108.51 +0.35 (+0.32%)

As of 07/25/2025 06:42 PM Eastern

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time